News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck KGaA (MKGAF.PK) Says Erbitux Fails in Stomach Cancer Trial


7/5/2012 7:14:17 AM

Merck KGaA’s Erbitux cancer treatment failed to help patients with advanced stomach tumors in a late- stage clinical trial, dealing the company a setback in the effort to expand sales of its second-biggest-selling medicine. The drug, combined with two other medicines, didn’t extend the length of time that patients lived without their disease getting worse, the Darmstadt, Germany-based company said in a statement today. The results are the second disappointment this year for Erbitux. The company said May 9 the drug failed to show a benefit for stage-three colon cancer patients when given with chemotherapy as a way to prevent the cancer’s return following tumor removal. Merck’s forecast in May for company revenue to reach as much as 10.7 billion euros ($13 billion) in 2014 didn’t include approval of Erbitux for use in additional cancer types.

Read at Bloomberg
Read at RTT News
Read at AFP
Read at Wall Street Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES